The associations of ANGPTL4, APOC3, and LPL GRS with CAD and T2D remained consistent in direction and significance when tested in combination with either the HMGCR and PCSK9 GRS, suggesting that LPL pathway activation may be an effective therapeutic target in lowering CAD risk in combination with statin or PCSK9 inhibitor treatment. This evidence concerns the gene APOC3 and coronary artery disorder.